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ABSTRACT 
The objective of this work was to formulate and evaluate sustained release epidural injection of analgesic drug diclofenac sodium used in 
chronic lower back pain. The formulation composed of a thermosensitive polymer Pluronic F127 (20%) and sustained release copolymers 
HPMC K100M (1%) and HPMC K4M (0.5%) optimized using 32 factorial design. The formulation was found to be clear, colorless, sterile, 
syringeable through 18gauge, forming a stable gel at 37°C with a gel strength of 9.67g/cm. The drug release was found to be 98.13% in 72 hrs. 
The formulation was found to be stable at refrigerator temperature of 5°C for a month. Thus, a stable parenteral formulation was developed 
that can be an appropriate and convenient approach for patients requiring frequent parenteral administration, reducing recurrence of dosage 
and ultimately expanding patient comfort and satisfaction in case of chronic ailments.  
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INTRODUCTION  
The lower back supports the weight of the upper body and 
provides mobility for everyday motions such as bending and 
twisting. Muscles in the low back are responsible for flexing 
and rotating the hips while walking, as well as supporting the 
spinal column. Nerves in the low back supply sensation and 
power the muscles in the pelvis, legs, and feet. Most acute 
low back pain results from injury to the muscles, ligaments, 
joints, or discs. The body also reacts to injury by mobilizing 
an inflammatory healing response. While inflammation 
sounds minor, it can cause severe pain. 
Symptoms of lower back pain are usually described by type 
of onset and duration i.e. Acute pain comes on suddenly and 
lasts for a few days or weeks, and is considered a normal 
response of the body to injury or tissue damage, Subacute 
low back pain is usually mechanical in nature (such as a 
muscle strain or joint pain) but is prolonged and Chronic 
back pain which is defined as lower back pain that lasts over 
3 months, this type of pain is usually severe, does not 
respond to initial treatments, and requires a thorough 
medical workup to determine the exact source of the pain. It 
is also possible for low back pain to develop with no 
definitive cause. When this happens, the primary focus is on 
treating the symptoms rather than the cause of the 
symptoms and the patient’s overall health.1 
Various treatments are available for low back pain such as 
physical therapy, surgeries, and medications. The 
medications includes topical such as Aspercreme, Ben-Gay, 
Oral medications (NSAIDs, Narcotics, Muscle relaxants, 
steroids, etc) and injections. Epidural steroid injections are 
common treatment option for many forms of low back pain, 
however the effects of the injection tend to be temporary, so 
it need to be used in combination with comprehensive 
rehabilitation program, providing relief from pain for one 
week up to one year.2 
The rationale behind injecting drug into the epidural space 
adjacent to the spinal nerve is that it will combat the 
inflammatory response and thus reduce pain. The 
inflammation can lead to direct neuronal activity, as well as 
swelling and mechanical compression of the nerve within the 
intervertebral foramen so to facilitate earlier pain relief and 
return to full function, for rapid effects of medication on 
cerebrospinal tissues or meninges, medication can be 
administered into the epidural space of the spinal cord. This 
technique avoids absorptive problems otherwise presented 
by the blood–brain barrier. So far, to our knowledge, for 
general clinical epidural use there is only one slow-release 
liposome product of morphine available on market 
(DepoDur®).3,4  
Diclofenac is non-steroidal anti-inflammatory drug (NSAID), 
indicated in the relief of all grades of pain and inflammation 
associated with a wide range of conditions, including 
arthritic conditions, acute musculo-skeletal disorders and 
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other painful conditions resulting from trauma. Usual 
strength of diclofenac injection is 25 mg per ml. 5 
In-situ forming polymeric formulations are drug delivery 
systems that is in sol form before administration in the body, 
but once administered, undergoes gelation, In-situ to form a 
gel.  
It provides accuracy of dose, increase residence time and 
bioavailability at targeted site, reduction in dosing 
frequency; prolong duration of action and patient 
compliance. Side effects such as quick release, less residence 
time at targeted site of action of conventional injections can 
be overcomed. A long acting, single dose epidural 
formulation would improve clinical treatment of various pain 
states therefore; an injectable epidural in situ gel is being 
developed. 6 
MATERIALS AND METHOD 
MATERIALS   
Diclofenac Sodium was obtained as a gift sample from 
Emcure Pharmaceuticals Pune.   PluronicF127 was provided 
by Ana lab fine chemical, Mumbai. Hydroxy propyl methyl 
cellulose K100M, K4M (HPMC K100M, HPMC K4M) was 
provided by Chemica-biochemic-reagents, Ottochemie, 
Pvt.Ltd. Sodium chloride was provided by LobaChemiePvt. 
Ltd. Mumbai. 
METHOD 
1. Optimization study -  
A response surface statistical experimental design was used 
to optimize the effect of different independent factors on 
dependent variables. The variables were investigated using a 
32 full factorial designs using Design-Expert Software® 11 
(Stat-Ease, Inc., USA) 
This design was based on a 32 factorial design, three 
replicates of the central run, leading to 9 sets of possible 
combinations, allowing each experimental response to be 
optimized. Different batches were prepared with different 
independent factors at different levels and responses. The 
experiments were designed to study effect of three 
independent variables namely the Syringeability of the 
formulation through 18 G needle, highest gel strength and % 
drug release for prolonged period of time i.e. for 3 days.
 
Table 1: Formulation combination as per the 32 full factorial designs 
Formulation code Pluronic F 127 % (W/V) HPMC K100M % (W/V) HPMC K4M % (W/V) 
F1 20 0.5 0.5 
F2 20 1 0.5 
F3 20 2 0.5 
F4 20 0.5 1 
F5 20 1 1 
F6 20 2 1 
F7 20 0.5 2 
F8 20 1 2 
F9 20 2 2 
 
The quality of the fitted model was expressed by the 
coefficient of determination R2, and its statistical significance 
was checked by an F-test (analysis of variance) at the 5% 
significance level. The statistical significance of the 
regression coefficients was determined by using the t-test 
(only significant coefficients with p-value < 0.05 are 
included). The optimum processing conditions were 
obtained by using graphical and numerical analysis based on 
the criteria of the desirability function and the response 
surface.7 
2. Preparation of Formulation 
The method of preparation of in situ gel involved slow 
addition of thermoresponsive polymer i.e. Pluronic F127 
with continuous stirring in required quantity of cold water, 
followed by slow addition of drug in the polymer solution. 
This solution formed was kept in refrigerator at 5°C for 24 
hrs to dissolve completely and form a uniform drug solution. 
The required quantities of other excipients like copolymer 
HPMC K100M, HPMC K4M and tonicity adjusting agent i.e. 
NaCl were added to this solution under continuous stirring 
to form a homogeneous, clear colourless solution. The 
formulation was filled aseptically in transparent glass 
ampoules of 3ml and sterilized by autoclaving at 121°C at 15 
psi for 20 min and stored at refrigerator condition.8, 9, 10, 11 
Evaluation of Formulation 
1. Appearance & pH  
The optimized formulation was evaluated for visual 
appearance. The pH of the solution form was measured 
using standardized digital pH meter (Deluxe pH meter 
101/EI) by dipping glass electrode in sufficient volume of 
20ml of formulation in beaker.12 
2. Gelation Temperature   
Gelation temperature was determined by modification of 
Miller and Doravan technique.   A 3 ml aliquot of solution 
was transferred to test tubes immersed in a cryostatic water 
bath at 20° C and sealed with aluminium foil. The 
temperature of water circulation bath was increased with 
increments of 1°C and left to equilibrate for 5 min at each 
new setting. The samples were examined for gelation which 
was said to have occurred when the meniscus would no 
longer move upon tilting through 90°angle.8, 9, 10 
3. Gel strength 
Gel strength was determined by Surimi test using Texture 
Analyzer (Texture Pro CT V1.4). Formulation (20 ml) was 
placed in 25 ml beaker and gelled using heating plate at 
37˚C. The probe (TA 3/100) was allowed to traverse the gel 
up to 1 cm at a speed of 1mm/s. The load reading was taken 
in g/cm for gel strength.13 
4. Viscosity 
Viscosity was measured on Brookfield viscometer using RV 
(spindle no. 21) and T-type helipath spindle (spindle no. 
S21). Viscosity was analyzed by subjecting the sample at 
room temperature and 37˚C and variable shear stress.14 
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5. Syringeability 
Syringiablity of the formulations was assured using 18 to 22 
gauge needles. Formulation was withdrawn into identical 5 
ml disposable syringes placed with needles to a constant 
volume (3 ml). The solutions which were easily passed from 
a particular syringe were termed as pass and the ones which 
were difficult to pass were termed as fail.12 
6. Drug content estimation  
The quantity of formulation containing about 50mg of 
Diclofenac Sodium was taken and shaken with 60ml of 
methanol in a 200-ml volumetric flask and was diluted up to 
volume with methanol. 5ml of this solution was diluted up to 
100ml with methanol was prepared and analyzed by UV 
spectrophotometer and HPLC. The concentration of the drug 
present in the formulation was computed from the 
calibration curve using the equation y = mx+ c.15 
7. Sterility Testing 
Sterility testing was performed as per the IP 2014. The 
formulation was incubated for not less than 14 days at 30-
35°C (anaerobic condition) in the alternative fluid 
thioglycolate medium to observe the growth of bacteria & at 
20°C-25°C (aerobic condition) in soyabean casein digest 
medium to observe the growth of fungi in formulation. The 
test was performed using positive and negative controls.16, 17 
8. In-vitro Drug Release Studies 
The in vitro drug release studies of in-situ forming gel 
sustained release injectable of diclofenac sodium were 
conducted using Orbital Shaking Incubator (REMI model) 
maintained at 37°C and agitated at 30 rpm under mild 
agitation for 3 days conditions similar to physiological 
conditions. This speed was kept slow enough to prevent the 
formulation gel matrix from breaking.  Phosphate buffer (pH 
7.4) was used as the dissolution medium.  At specific time 
intervals (1, 24, 48 and 72hrs), 1 ml of aliquots was 
withdrawn and replaced with a fresh medium to maintain 
sink conditions. Aliquots withdrawn were filtered, suitably 
diluted and analyzed using UV spectrophotometer (V-530, 
Jasco) at 281 nm. The percentage cumulative drug release 
(% CDR) was calculated using an equation obtained from a 
calibration curve.18, 19, 20 
9. Accelerated Stability study  
 Stability studies were conducted on optimized formulation 
according to the guidelines of International Conference on 
Harmonization (ICH). A sufficient quantity of formulations 
were kept at room temperature i.e. at 25°C ± 2°C/60% ± 5% 
RH, refrigerator i.e. at 5°C± 3°C and accelerated 
conditions(40°C±5°C/75±5%RH) for 1 month. After 1month 
samples were evaluated for appearance, pH, clarity, gelation 
temperature, % drug content and in vitro drug release.21, 22 
RESULTS AND DISCUSSIONS 
Optimization study  
The design of experiment (DOE) is an approach in which 
process variables are first screened and then optimized to 
determine best settings for the variables. The full factorial 
design is a quadratic design which requires 3 levels (-1, 0, 
+1) for each factor. The concentration of HPMC K100M and 
HPMC K 4M were selected as the independent variables 
whereas Syringeability, Gel strength and Drug release were 
selected as the dependent variables. The Formulations from 
F6 to F9 failed to pass through 18 Gauge needle and were 
not syringeable due to high viscosity though they showed 
highest gel strength, so they were not taken further for drug 
release. The interactions between the factors were 
demonstrated using 3-D graphs. The experimental values 
obtained were compared with those predicted by the 
mathematical models. The data generated is given in Table 2 
which was analyzed using Design Expert software version 
11.0 and polynomial equations were obtained for the same. 
Table 2: 32experimental design with response 
Formulation 
code 
Gel strength 
(g/cm) 
% Drug release 
(At 72 hrs) 
F1 7.28 105.46 
F2 9.67 98.13 
F3 10.66 84.59 
F4 10.17 94.23 
F5 9.51 87.43 
F6 13.3 - 
F7 12.11 - 
F8 11.94 - 
F9 14.07 - 
 
Response Surface plots: 
(1) Gel strength 
 
Figure 1: Response surface of gel strength 
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The optimized batch showed gel strength of 9.67g/cm. This 
is obtained by synergistic effect of HPMC K100M and HPMC 
K4M. Pluronic F127 is a non-ionic triblock copolymer having 
central hydrophobic chain of polyoxypropylene chain and 
lateral identical hydrophilic polyoxyethylene chains (PEO-
PPO-PEO). Pluronic F127 shows thermo-induced changes in 
micellar properties. They have some important drawbacks 
that may limit their applicability, such as their weak 
mechanical strength, not stable and rapid dissolution. The gel 
must have the sufficient gel strength to withstand the various 
body shear forces. Alone Pluronic F127 does not impart gel 
strength. So copolymers HPMC K100M and HPMC K4M were 
added. Both show the response on gel strength and stability. 
As shown in figure 1, response surface plot showed that as 
the concentration of polymers increases, the gel strength 
increases. 
In the equation, A & B having positive effect on gel strength. 
The interaction terms A & B have synergistic effect on gel 
strength. Final Equation of gel strength in terms of Coded 
Factors 
Gel strength= + 11.32+1.46*A+1.68*B.... (1) 
Where, A is concentration of HPMC K100M and B is the 
concentration of HPMC K4M. 
 
 
(2) Drug Release: 
 
Figure 2: Response surface for Drug Release 
As shown in Figure 2, response surface plot showed the 
combined effect of HPMC K 100M and HPMC K4M on drug 
release. In order to obtain a sustained release over a 3 days 
period, it was necessary for the in situ gel formed to have a 
sufficient strength and stability that was achieved by adding 
copolymers to the thermoreversible polymer. HPMC K100M 
was initially added that prolonged the release but showed 
initial burst release due to lack of uniform and coherent gel. 
So, another copolymer HPMC K4M was added that reduced 
the burst release and prolonged the release. 3D response 
surface plot for drug release showed that with increase in the 
concentration of both the copolymers release is prolonged. 
Final Equation of Drug release in terms of Coded Factors: 
Drug release = +44.72-20.06*A-47.72*B… (2) 
Where, A is concentration of HPMC K100M and B is the 
concentration of HPMC K4M. In this case, A and B were found 
to be significant model terms. The negative sign indicates an 
antagonistic effect or inverse effect of  A and B on the drug 
release.  The negative sign of A and B both polymer is 
indicating that lower the concentration of polymers, the 
higher will be the drug release. The low coefficient of A 
indicated that HPMC K 100M concentration affected drug 
release to a greater extent than HPMC K 4 M concentration 
due to high viscosity obtained with K100M than K4M. 
Analysis of variance (ANOVA) has been designed to 
determine the contribution and interaction of each variable 
to the model. The F distribution is a forecast proportion used 
by the analysis of the distribution of variances. The value of F 
would equate to one if they are equal. The F value of the 
ANOVA is the model mean square (MS) to the corresponding 
model mean square error. The higher the ratio, the higher 
the F value and the more likely the variance that the model 
contributes is significantly higher than a random error. 
The conclusion is based on the analysis of variance that the 
selected design sufficiently represents the statistics 
formulation of a sustained release parenteral drug delivery 
system. 
The ANOVA analysis of the linear  model indicated that the 
model was significant (p<0.05) also endorsed by the large F 
value and with the adequate Precision (ratio>4) was 
observed as shown in Table 3 and validation of the Response 
Surface Methodology are shown in Table 5.
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Table 3: ANOVA studies 
Response 
Variables 
F value P value Adj R2 Pred R2 
Adequate 
Precision 
Gel strength 20.21 0.0022 0.8277 0.7172 12.4543 
% Drug Release 15.30 0.0044 0.7814 0.5927 10.0593 
 
Table 4: Desirability function of optimized formulation 
Formulation code HPMC K100M (%W/V) HPMC K4M (%W/V) Desirability 
F2 1 0.5 1.000 
 
Table 5: Validation of the Response Surface Methodology (RSM) 
Responses Experimental value Predicted value % Predicted error 
Gel strength 9.67 9.14 0.53 
% drug release 98.13 99.021 0.891 
 
Appearance and pH 
The optimized formulation was colorless, clear and 
transparent. The clarity of formulation indicates that all the 
ingredients were dissolved completely showing no visible 
residue or particulate matter in the formulation. Autoclaving 
sterilization did not have effect on the stability of 
formulations. The pH of the solution form was found to be 
7.1-7.4 at room temperature which is suitable for epidural 
administration. 
Gelation temperature 
The optimized formulation contains 20% pluronic F127 
(P407) that showed gelation at the 37°C temperature i.e. 
body temperature. It was found that with increasing 
concentration of the polymer, gelation temperature 
decreased as shown in fig. 3. Pluronic F127 is a triblock 
copolymer with a central hydrophobic chain of PPO and two 
identical hydrophilic chains of PEO(PEO-PPO-PEO). In 
solution form i.e. in water, as the concentration of pluronic 
F127 increased, micelle formation occurs, followed by 
aggregation of micelle. The gel phase could occur when the 
concentration is above the micellar concentration. The 
hydrogen bonding between PPO chains and water keeps the 
hydrophobic portions of the pluronic separate when the 
material is dissolved in cold water. When the temperature is 
increased, the disruption of hydrogen bonding occurrs and 
hydrophobic interactions causes gel to be formed. 
 
 
Fig 3: Effect of concentration of PF127 on gelation temp 
 
Gel strength 
Gel strength of optimized formulation was found to be 9.67 
g/cm which was sufficient to maintain the gel stability over 
the prolonged time period. Gel strength provides an 
overview of the mechanical properties of gel. It also signifies 
the ability of gel to withstand shear forces in the body for 
prolonged period of time. The Gel strength of formulation 
was important variable dependent on the concentration of 
gelling agent i.e. Pluronic F127. Pluronic F127 (20%) reveals 
that it does not have sufficient gel strength to maintain for 
prolonged time so copolymers were added that increased the 
gel strength, by forming hydrophobic interactions with 
Pluronic F127. 
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Viscosity 
The viscosity of optimized formulation in solution form was 
found to be 110cP and the viscosity of gel form was found to 
be 1180cP. To administer formulation easily into the body it 
should possess optimal viscosity in solution form. This 
viscosity is sufficient for ease of administration of injection. 
Further the formulation undergoes phase transition from sol 
to gel transition upon contact with body temperature. The 
viscosity of polymer solutions is the result of hydration of 
polymer chains. 
Syringeability  
The optimized formulation was easily passed through the 
needle gauge 18. This needle size was suitable for epidural 
injection.  
 Drug content 
The percentage drug content in the formulation was 
calculated and found to be 98.62%, indicating insignificant 
loss of drug during the formulation. 
 Sterility testing 
Test for bacteria & fungi 
The test samples were observed for turbidity after 14 days. It 
was showing clear solution. So the formulation was found to 
be free from bacteria and fungi and hence it was found to be 
sterile that was suitable for parenteral administration. Thus 
the sterility of the formulation may be attributed to aseptic 
process of preparation and filling the container and 
autoclaving at 121°C at 15 psi for 20 min. 
 
Table 6: Observations for bacterial& fungal growth 
Sample Observations Inference 
Bacteria  Fungi  
Positive control Turbid Turbid Growth 
Negative control Clear Clear No growth 
Test sample Clear Clear No growth 
 
In vitro Release study 
The in vitro release of the optimized formulation F2 was 
found to be 98.13% after completion of 3 days. The Fig.4 
shows the comparative in vitro drug release of all batches. 
The drug release was regulated by erosion and diffusion 
mechanism. The formulation got converted into gel form as 
the formulation was added to the preheated phosphate 
buffer pH 7.4 at 370C. The thermoresponsive polymer i.e. 
pluronic F127 undergoes phase transition from sol-gel and 
formed barrier for drug release. As the time passes the outer 
layer became more hydrated and the polymer chains become 
fully relaxed and leading to erosion from the surface. 
Simultaneously, The hydrophilic copolymer HPMC K100M 
and K4M being swellable, polymer started swelling and drug 
molecules began to move out of gel matrix by diffusion when 
exposed to the media. As the concentration of HPMC K100M, 
HPMC K4 M copolymer increases, drug release was retarded.  
Accelerated Stability testing 
Studies of stability indicated that optimized formulation was 
physically and chemically stable at ambient temperature i.e. 
at 25 ° C ± 2 ° C/60 % RH ± 5 % RH and at accelerated conditi
ons 40 ° C ± 2 ° C/75 % RH ± 5 %RH and at refrigerator condi
tions i.e. at 5 ° C ± 3 ° C for a period of 1 month. From 
stability studies, it was observed that the formulation of 
Diclofenac Sodium was stable at selected storage conditions 
with most suitable storage condition at the refrigerator 
temperature. It showed that there was no change in colour, 
gelation temperature but slightly increases in gel strength 
and slightly decreases in pH, gel strength and in vitro drug 
release profile at 40°C. 
 
Fig: 4 In-vitro drug release
 
Table 10: Stability studies results after 1 month 
 
0
20
40
60
80
100
120
0 hours 24 hours 48 hours 72 hours
%
 D
ru
g 
R
e
le
as
e
 
Time (hours) 
F1
F2
F3
F4
F5
Evaluation 
parameters 
Initial 
After storage at room 
temperature 
(25±2°C/60±5 % RH) 
 
After storage at 
Accelerated condition 
(40±2oC/75±5%) 
After storage at 
Refrigerator temp 
(5°C±3°C) 
Appearance clear,colorless clear, colorless clear, colorless clear, colorless 
pH 7.4 7.3 7.2 7.4 
Gelation temperature 37° C 37° C 37° C 37° C 
Gel strength (g/cm) 9.67 9.36 9.50 9.17 
Drug content 98.62 97.93 96.59 98.12 
Syringeability Passes Passes Passes Passes 
In vitro drug release at 
72 hrs after 1 month 
98.13 97.70 97.81 97.99 
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CONCLUSION- 
Thus a stable and novel formulation of Diclofenac Sodium as 
a sustained release epidural injection was developed and 
evaluated for treatment of chronic lower back pain. It is an 
alternative to the conventional and other sustained release 
formulations owing to its ability to achieve a prolonged 
release with single administration of drug to the target site 
(epidural space),reduced frequency of administration and 
improved patient compliance. Also the formulation involves 
less complicated fabrication and ease of administration. 
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